Background: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. As there was a nationwide participation in The Netherlands, we studied the variations in patterns of care in the Comprehensive Cancer Centre Regions (CCCRs) and compliance with national guidelines.
introduction
In women with hormone-sensitive early breast cancer, adjuvant endocrine therapy improves disease-free survival (DFS) and overall survival (OS) [1] . For many years, tamoxifen has been the gold standard in this setting. Third-generation aromatase inhibitors have shown superior efficacy compared with tamoxifen in postmenopausal women with metastatic/ advanced breast cancer [2] . Therefore, many clinical trials have investigated the value of these drugs as adjuvant therapy in hormone-sensitive postmenopausal breast cancer [3] [4] [5] [6] [7] [8] . The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial (Netherlands Trial Register NTR267) is a randomised international trial comparing the efficacy and safety of 2.5-3 years of adjuvant tamoxifen followed by 2.5-2 years of exemestane versus 5 years of exemestane in postmenopausal women with hormone-sensitive early breast cancer. In The Netherlands, this trial has been activated in 76 of a total of 123 Dutch centres, both academic and community hospitals, throughout the country.
In line with international developments, an evidence-based/ expert-based guideline on the treatment of breast cancer exists in The Netherlands, coordinated by the National Breast Cancer Organisation of The Netherlands (NABON). A multidisciplinary working party, consisting of representatives from different disciplines involved in breast cancer care, as well as from the patient advocacy group, is responsible for its contents as well as regular updates. The implementation process is being facilitated and stimulated by working parties in original article the nine Dutch Comprehensive Cancer Centre Regions (CCCRs). During the largest accrual period of the TEAM trial, the NABON guideline version 2002 was prevailing (www.oncoline.nl).
As adherence to the guideline is advised, differences with respect to breast cancer treatment may exist between hospitals and across different CCCRs. For The Netherlands, this has been reported in studies with respect to breast-conserving surgery (BCS), sentinel lymph node procedure (SLNP) and chemotherapy [9] [10] [11] . So far, data on adherence to the NABON guideline are scarce and were generated from retrospective population-based studies carried out in a particular CCCR, while no data are available on the variation in patterns of breast cancer care between all different CCCRs. As there was a nationwide participation, the TEAM trial offered the opportunity to evaluate the differences in patterns of care regarding local treatment strategies and adjuvant chemotherapy between the various CCCRs and the adherence to the national guideline.
methods organisation of breast cancer care in The Netherlands
In The Netherlands, a nationwide programme offering biannual mammography to women aged 50-70 years (later on 75) was initiated in 1989. In case of suspicious changes or abnormalities, the general practitioner is informed and refers the patient to the surgical department of one of the regional hospitals. The diagnostic work-up and therapy of breast cancer are carried out routinely in all hospitals. However, the number of patients annually seen and treated per hospital varies. The guideline advises that planning of local and systemic therapy should be discussed preoperatively by a complete multidisciplinary breast cancer team. As during the period that the TEAM study was running, not all hospitals had a dedicated breast cancer team, not all patients were discussed preoperatively, whereas this occurred postoperatively in almost all patients.
the TEAM trial
The TEAM trial is an international randomised phase III trial and was originally designed to compare 5 years of exemestane (25 mg/day) versus 5 years of tamoxifen (20 mg/day). However, the published data of the Intergroup Exemestane Study (IES) showed a significantly improved DFS with exemestane following 2-3 years of tamoxifen as compared with the standard 5 years of tamoxifen treatment [12] . Therefore, the design of the TEAM study was amended to compare 5 years of exemestane alone versus sequential therapy with 2.5-3 years of tamoxifen followed by 2.5-2 years of exemestane. Primary end points of the core protocol are DFS at 2.75 and 5 years; secondary end points include OS, incidence of a new primary breast cancer and relative safety profiles [13] eligibility criteria for the Dutch TEAM trial Eligibility criteria were postmenopausal women with histologically confirmed invasive breast cancer, positive estrogen receptor (ER) and/or progesterone receptor (PgR) status, having undergone intentionally curative surgery and having an indication for adjuvant endocrine therapy according to the NABON guideline. Postmenopausal status was defined as follows: patients with intact uterus and natural amenorrhoea for >1 year and history of bilateral surgical oophorectomy and no hormone replacement therapy. In case of doubt, follicle-stimulating hormone and estradiol concentrations had to be within the postmenopausal ranges. Adjuvant chemotherapy preceding the start of endocrine therapy was allowed. Radiotherapy was given according to the NABON guideline whereby no recommendation was given regarding the sequence of radiotherapy and chemotherapy. Endocrine treatment had to be started within 10 weeks after completion of definitive surgery or chemotherapy.
Patients were ineligible in case of inflammatory breast cancer, clinical skin ulceration/infiltration of local skin metastasis, positive supraclavicular lymph nodes, evidence of distant metastases, neoadjuvant chemotherapy, participation in another clinical trial interfering with the end points of the TEAM trial, other clinically relevant or serious illnesses, previous breast cancer or history of another malignancy within the preceding 5 years (except for adequately treated carcinoma in situ of the uterine cervix or basal squamous cell carcinoma). Hormone replacement therapy had to be stopped >4 weeks before randomisation.
Patients received oral and written information and provided informed written consent. The trial has been approved by the appropriate regulatory and ethics authorities of the different participating hospitals.
data collection
From each patient, the following data were recorded: patient characteristics (age, length, weight, menopausal status and medical history), tumour characteristics (primary disease site, histological grade, Mitotic Activity Index score, tumour-node-metastasis stage and ER and PgR status), local therapy data [dates and type of surgery, SLNP, axillary lymph node dissection (ALND) and radiotherapy (to the breast or to the chest wall)] and chemotherapy data. Original pathology reports were centrally collected and checked for tumour characteristics. Central pathology review was not carried out for this analysis but will be carried out for all Dutch patients within the context of an ongoing international project [14] . Table 1 . The mean age at diagnosis was different between CCCRs (one-way ANOVA overall P < 0.001). Post hoc analysis with Bonferroni correction revealed that this difference was caused by the age of patients in one CCCR [Integraal Kankercentrum Limburg (IKL), mean age 71 years (SD 10)]. Excluding patients from this CCCR, age at diagnosis of the other CCCRs was similar (mean age 65 years, SD 9, P = 0.297).
Overall, 46% of patients had a T1 tumour, ranging between 39% and 50% among the CCCRs (P = 0.200). The frequency of node-negative disease ranged from 25% in the Integraal Kankercentrum Noord (IKN) to 45% in the Integraal Kankercentrum Oost (IKO) (P < 0.001). As hormone sensitivity was an inclusion criterion for the TEAM trial, the ER status was available for all patients. The PgR status was not regularly assessed in five CCCRs, particularly in the Integraal Kankercentrum Amsterdam (IKA) and IKN region (PgR status not available in 14% and 25%, respectively). Human epidermal growth factor receptor 2 overexpression was not routinely assessed as at that time it did not have therapeutic consequences.
local therapy
Overall, more women underwent a mastectomy compared with BCS (55% versus 45%, respectively; Table 2 ). Although tumour size was not significantly different between the various regions, the mastectomy rate ranged between 45% [Integraal Kankercentrum Zuid (IKZ)] and 70% (IKL) (P < 0.001). In all CCCRs, mastectomy was carried out more often for larger tumours. For T1 tumours, mastectomy rates ranged between 20% and 55% (P < 0.001, data not shown). Results of univariate analysis regarding type of surgery with age at diagnosis, tumour size, body mass index (BMI), CCCR and physician who included the patients (medical oncologist versus surgeon) as variables indicated that all factors except BMI were statistically significant (Table 3) . In multivariate analysis, age, lower T stage and CCCR remained independent factors for BCS (Table 4) . For the CCCR Integraal Kankercentrum Rotterdam (IKR), we separately investigated whether BCS rate was related to the travel distance to a radiotherapy facility. This could not be demonstrated (data not shown).
An SLNP was carried out in 68% of patients, ranging from 42% [Integraal KankercCentrum Spectrum Twente (IKST)] to 79% (IKO) (P < 0.001; Table 2 ). All variables included in univariate analysis were significant (Table 3) . In multivariate analysis, it was observed that favourable tumour stage, BCS and CCCR were associated with more SLNPs (Table 4 ). Almost 80% of the patients underwent an ALND (range 67%-83%), being different between the CCCRs (P < 0.001). On an average, 14 (range 0-46) lymph nodes were examined, being consistent with the guideline recommendation.
Radiotherapy to the breast (with/without boost) or chest wall was given in 57% of cases (Table 2) . Ninety-five percent (1168of 1228) of the patients who underwent BCS received radiotherapy. The frequency of radiotherapy after mastectomy ranged between 17% and 33% (P = 0.043). In multivariate analysis, age, larger tumour stage, BCS and more positive lymph nodes were predictive for receiving radiotherapy (Table 4) . Adjuvant chemotherapy was given in 43% of women <70 years of age varying between the CCCRs (P < 0.001; Table 2 ). For the age groups <50, 50-59 and 60-69 years, this was 86%, 65% and 21%, respectively (P < 0.001, data not shown). In multivariate analysis, younger age at diagnosis, larger tumour stage, more positive nodes, worse histological grade, the physician who included the patient andCCCR were prognostic factors for administration of chemotherapy (Table 4) . In most CCCRs (seven of nine), adriamycin and cyclophosphamide or epirubicin and cyclophosphamide was administrated in the majority of the patients receiving chemotherapy. More 5-fluorouracil, adriamycin and cyclophosphamide or fluoruracil, epirubicin and cyclophosphamide was administrated in the two CCCRs where cyclophosphamide, methotrexate and 5-fluorouracil also was given in 20% patients.
sequence of radiotherapy and chemotherapy
The sequence of administration of radiotherapy and chemotherapy, respectively, was different in the various CCCRs (P < 0.001; Table 2 ). Radiotherapy was almost always given after chemotherapy in the IKL, IKN and IKR region (>90%). In the Integraal Kankercentrum Midden Nederland and IKO region, the majority of patients received radiotherapy before chemotherapy (69% and 83%, respectively). This policy, however, was not consistent throughout the hospitals in these regions (data not shown). In the IKA and IKZ region, some patients received chemotherapy in combination with radiotherapy.
discussion
To our knowledge, this is the first report describing variations in patterns of breast cancer care regarding local treatment 
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strategies and adjuvant chemotherapy in all Dutch CCCRs. In view of the large number of included patients and the nationwide participation in the TEAM trial, the results of the current analysis may be considered as a reflection of the management of postmenopausal breast cancer patients in The Netherlands. We have no indication that patients within the TEAM trial were treated differently with respect to locoregional therapy and adjuvant chemotherapy compared with postmenopausal breast cancer patients outside the TEAM trial.
Our results indicate that, despite the existence of a national breast cancer guideline, patterns of care varied widely throughout the country. Age at diagnosis and tumour size were not significantly different in the various CCCRs, except for the IKL region, where due to a concurrent adjuvant chemotherapy trial, less young postmenopausal patients were included. In only 46% of cases, the tumour was <2 cm. This can be explained by the fact that during inclusion of the TEAM study, only larger tumours original article Annals of Oncology or small tumours with grade III or small tumours with positive nodes were candidates for endocrine therapy according to the pending guidelines. The observation that in some CCCRs, information on the PgR status was lacking despite the national recommendation to determine both ER and PgR status can be explained by the fact that some pathology laboratories only determined the PgR status in case of a negative ER status as with a positive ER status; knowledge on the PgR status had no consequences with respect to the type of adjuvant systemic therapy. This observation is in accordance with data from other aromatase inhibitor trials (Table 5) . More patients were treated with mastectomy compared with BCS. The choice concerning the type of breast surgery is known to be influenced by the preference of patients, doctors (especially the surgeon being a key player) and geographical factors [15] [16] [17] [18] [19] [20] . Regarding the latter, the absence of a local radiotherapy unit as well as travel distance and facilities can play a role. The higher age of patients in the IKL region might explain the higher rate of mastectomies. In contrast, this does not explain the high rate of mastectomies in the IKR region (67%). Differences in surgical choice were also seen in the 'Anastrozole, Tamoxifen, Alone or in Combination' trial [21] . In this trial, nationality (United States versus UK versus rest of the world) was found to be an independent determinant of type of surgery; American women were more likely to undergo a mastectomy than women in the UK. In accordance with our findings, the accessibility to a radiotherapy facility was not found to be a major determinant for less or more extensive surgery. According to the guideline, radiotherapy was given after BCS in the majority of cases (95%). In previous studies, age appeared to be a stronger predictor than co-morbidity with respect to omitting radiotherapy, especially in the oldest age group [22, 23] . In view of the growing proportion of the elderly for the next decades, this and other issues regarding elderly patients are worthwhile exploring.
In most CCCRs, SLNP was carried out in at least 70% of patients. Low percentages were in the IKST (42%) and IKR (58%) region, where in some hospitals, this procedure had only been introduced since [2003] [2004] . We expect that the differences in SLNP between the CCCRs will disappear over time because the SLNP has now been implemented nationwide. Whether a different percentage of clinically positive nodal disease at presentation might be another explanation is unclear as no information about this issue is available in our database. On an average, all regions fulfilled the national recommendation to examine at least 10 lymph nodes at ALND. Not all patients with a positive sentinel lymph node received an ALND, which in part may be explained by concomitant participation in the ongoing AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial [24] . In this trial, patients with clinically negative nodal disease and a positive SLNP were randomly allocated between ALND or radiotherapy to the axilla.
Despite the fact that most patients had node-positive disease, only a minority was treated with chemotherapy. This is in part a reflection of the NABON guideline of 2002, in which chemotherapy is only recommended for fit patients under the age 70 years with unfavourable tumour characteristics ( ‡N2 disease). Remarkably, fewer patients received chemotherapy in the IKO region since in some hospitals, adjuvant chemotherapy was erroneously thought to be an exclusion criterion for this trial. Our data are in accordance with the findings of IES, showing substantial geographical differences in indications for and choice of adjuvant chemotherapy [25] . Differences regarding chemotherapy administration are also seen between the various aromatase inhibitor trials, although this can be partly explained by the different trial eligibility criteria (Table 5) .
CCCR was, even after correction for relevant factors, an independent predictor for type of surgery, SLNP and adjuvant chemotherapy. This indicates that implementation of and interpretation and adherence to the national guidelines varies between CCCRs. Different reasons have been reported for not adhering to guidelines including physician-related factors, patient's age, patient/doctor preferences, comorbidity burden, [15, 17, [26] [27] [28] . Because of the retrospective nature of this analysis, it was not possible to study the impact of most of these factors. However, in view of the ultimate goal of national and international guidelines and of the strong evidence that treatment in accordance to guidelines results in improved outcome for breast cancer patients, attention for improvement of guideline adherence is necessary [29] . In addition, these variations in locoregional and adjuvant chemotherapy policies might influence the end points of adjuvant studies with hormonal agents in postmenopausal women. This could be relevant as, in general, the benefit of aromatase inhibitors is small compared with antiestrogens. One way to address this issue further is focussing on the implementation of breast cancer teams. These multidisciplinary teams intend to coordinate, standardise and ameliorate breast cancer care and outcome. It has been demonstrated that 43% of patients advised and treated by a multidisciplinary team received a different treatment than when they were treated by a single specialist [30] . Also, the advice given by the multidisciplinary team was more in line with good clinical practice guidelines as compared with advices given by a single specialist, which particularly reflected their own discipline. Patients reported that physicians' recommendations greatly influenced their treatment decisions [31] . The implementation of newer adjuvant systemic therapies was strongly dependent on the activation of a multidisciplinary team resulting in an improved survival for respective patients [28] . Due to the lack of data concerning the availability of Dutch breast cancer teams, it was not possible to evaluate its effect in this analysis.
In conclusion, this analysis provides more insight into the patterns of care in postmenopausal early breast cancer patients in The Netherlands. Our data show that, despite a national breast cancer treatment guideline, major regional differences in treatment exist. These differences must be taken into account when evaluating a certain element of the therapy for breast cancer, for example, endocrine therapy comparing aromatase inhibitors with antiestrogens in postmenopausal women. In our opinion, in attempting to improve breast cancer care, it is important to increase and further evaluate adherence to guidelines. 
